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Canine Leishmaniasis Progression 
is Associated with Vitamin D 
Deficiency
A. Rodriguez-Cortes1, C. Martori1, A. Martinez-Florez1, A. Clop  2, M. Amills2, J. Kubejko2,  
J. Llull3, J. M. Nadal3 & J. Alberola1
The relationship between vitamin D deficiency and the risk of suffering from a plethora of health 
disorders, ranging from autoimmune processes to infectious diseases has been widely described. 
Nonetheless, the potential role of vitamin D in visceral leishmaniasis remains uncharacterized. In the 
Mediterranean basin, where the dog is leishmania’s main peri-domestic reservoir, control measures 
against the canine disease have shown beneficial effects on the incidence of human leishmaniasis. 
In this study, we measured the vitamin D levels in serum samples from a cohort of 68 healthy and 
disease dogs from a highly endemic area and we have also studied the relationship of these levels 
with parasitological and immunological parameters. The sick dogs presented significantly lower 
(P < 0.001) vitamin D levels (19.6 ng/mL) than their non-infected (31.8 ng/mL) and the asymptomatic 
counterparts (29.6 ng/mL). In addition, vitamin D deficiency correlated with several parameters linked 
to leishmaniasis progression. However, there was no correlation between vitamin D levels and the 
Leishmania-specific cellular immune response. Moreover, both the leishmanin skin test and the IFN-γ 
levels displayed negative correlations with serological, parasitological and clinical signs. Further studies 
to determine the functional role of vitamin D on the progression and control of canine leishmaniasis are 
needed.
Visceral leishmaniasis (VL) is a neglected disease provoked by protozoan parasites of the Leishmania genus. 
Mainly found in subtropical areas of Asia and Africa, Latin America, and Mediterranean basin, VL can be fatal if 
left untreated. 20,000 human deaths are attributed to VL annually (http://www.who.int/leishmaniasis/en/). The 
dog is the main peri-domestic reservoir of the etiological agent, the protozoan L. infantum and shares many 
clinico-pathological features with the human disease1. Most Leishmania-infected humans and dogs show an 
asymptomatic infection, with only 5–20% of the cases developing the patent disease over a variable period of 
time2, 3. Although the mechanisms that regulate the final outcome of the infection remain unknown, the cur-
rent knowledge suggests that the protective responses are associated with the activation of specific cell-mediated 
immunity and a Th1-proinflamatory immune response4. Recent studies show that Th17 cells act synergistically 
with the Th1 population to control L. infantum growth. The interleukin (IL)-17 A modulates some key regulatory 
cytokines including IL-10 and sustains IFN-γ production by Th1cells at sites of inflammation5. The active disease, 
however, has been linked to high antibody levels and a progressive Th2-deactivating immune response in the 
presence of a strong inflammatory reaction6. Increasing evidences suggest that the innate immune system could 
play a relevant role by promoting the appropriate inflammatory response against the parasitic invasion7.
Vitamin D is the precursor of the powerful steroid hormone calcitriol. Besides its well described effects 
on the calcium and phosphate homeostasis, several studies strongly suggest that vitamin D has a strong 
immuno-modulatory role triggered by its binding to the vitamin D receptor (VDR), which is expressed in several 
antigen-presenting cells such as monocytes, macrophages, and dendritic cells8, 9. The mechanisms by which vita-
min D modulates the immune function have been studied within different context involving multiple pathogens. 
One of the most profoundly investigated mechanisms involves the axis of low sunlight exposure, vitamin D defi-
ciency, and tuberculosis, which this has been a subject of study for over a century10. Moreover, it is now known 
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that vitamin D strengthens the innate immune system by inducing the expression of anti-microbial peptides, such 
as cathelicidin and β-defensin, in Mycobacterium tuberculosis-infected human macrophages11. These peptides 
carry out several anti-microbial functions by directly acting on the bacterial wall12, increasing the formation of 
reactive oxygen species, modulating cytokine expression13, and inducing autophagy, which is another relevant 
anti-microbial effector mechanism14. Recent studies have shown a direct effect of vitamin D on T and B cells, 
where it reduces the production of pro-inflammatory Th1 and Th17 derived cytokines15, 16, B-cell differentiation, 
and IgG secretion17. Vitamin D has also been linked as a risk factor of a plethora of autoimmune disorders, dia-
betes, cancer, and several infectious conditions such as toxoplasmosis, influenza, malaria, and acquired immune 
deficiency syndrome18–23. Interestingly, a recent cross-sectional study conducted in Ethiopia showed that more 
than half of the paediatric VL patients had vitamin D deficiency24.
The goal of the current study was to investigate whether vitamin D levels are associated with the progres-
sion of canine leishmaniasis (CanL). To this end, we aimed at determining the potential correlation between the 
levels of the stable circulating metabolite of vitamin D, calcifediol (25-hydroxyvitamin D; 25(OH)D) and the 
Leishmania-specific immune response and the parasitological status of both clinically healthy dogs and those suf-
fering from the disease. In addition, we investigated the genetic association of a single nucleotide polymorphism 
in the VDR gene to CanL susceptibility.
Results
Characterization of the canine population. Eighteen of the 68 dogs included in the studywere negative 
for Leishmania serology, Leishmania quantitative real-time PCR (qPCR) in blood, and also for the leishmanin 
skin test (LST), and were thus included in the group of “Non-Infected” animals25, 26. The remaining 50 dogs tested 
positive for, at least, one of the above tests, and they were considered as infected. Of these, 35 were clinically 
asymptomatic and 15 showed clinical signs of leishmaniasis.
The baseline characteristics of the three groups are shown in Table 1. The group of dogs suffering from clin-
ical leishmaniasis presented a median [interquartile range] clinico-pathological score of 13.0 [10.50–18.50], a 
value that is significantly above the equivalent measurement in the non-infected animals (P < 0.001). Their main 
clinical signs were cutaneous lesions and lymphoadenopathy accompanied by higher levels of β- and γ-globulins 
(P = 0.016, P < 0.001, respectively) and lower red blood cell counts (P < 0.001). On the other hand, the group of 
asymptomatic dogs showed a median clinico-pathological score of 3.0 [1.00–4.00], a value that was non- statisti-
cally different when compared to the non-infected cohort (2 [1.00–2.75]) (P = 0.240).
The three groups also showed statistically significant differences in the Leishmania-specific immunoglobu-
lin concentration, the parasite burden in blood, and the intensity of LST reactions (Table 1). The symptomatic 
animals developed a higher level of Leishmania-specific antibodies than the non-infected dogs (P < 0.001). 
Moreover, 73% of the sick dogs were positive to qPCR (Ct threshold 39) in blood whilst only 13% showed a 
positive LST reaction. In clear contrast, the asymptomatic dogs displayed a significantly weaker specific humoral 
response when compared to the disease group (P < 0.001). Moreover, 66% of the asymptomatic animals were LST 
positive, but only 34% presented detectable parasites in blood. We also measured Leishmania-specific cytokine 
production by peripheral blood cells. These results showed that the IFN-γ levels produced by asymptomatic dogs 
(615.3 [130.80–1579.00] pg/mL) were higher than those produced by symptomatic (32.7 [1.73–125.42] pg/mL) 
or non-infected dogs (67.3 [0.00–208.59] pg/mL) (P = 0.001, P = 0.004, respectively). There were no differences 
between non-infected and sick animals in their IFN- γ levels. Furthermore, the comparison of IL-10 production 
of the three groups of dogs was similar.
Vitamin D levels and canine leishmaniasis. As shown in Fig. 1, the dogs with patent disease pre-
sented significantly lower levels of 25(OH)D than the non-infected (P < 0.001) and the asymptomatic groups 
(P < 0.001). The median [interquartile range] levels of 25(OH)D in non-infected, asymptomatic, and sympto-
matic dogs were 31.8 [25.95–34.65], 29.6 [24.64–40.03], and 19.6 [10.62–25.14] ng/mL, respectively. In addition, 
vitamin D levels significantly correlated with the clinico-pathological score (P < 0.001), serology (P = 0.002), and 
parasite burden (P = 0.005) in blood samples (Fig. 2). We did not find a significant correlation between 25(OH)
D levels and Leishmania-specific IFN-γ or IL-10 production. Whilst IL-10 was not correlated with any of the 
parameters under evaluation, the IFN-γ levels were positively correlated with LST reaction (ρ Spearman = 0.386, 
P = 0.008) and negatively correlated with the clinico-pathological score (ρ Spearman = −0.400, P = 0.006), serol-
ogy (ρ Spearman = −0.469, P = 0.001) and parasite burden in blood (ρ Spearman = −0.369, P = 0.012).
Univariate logistic regression analysis showed that only vitamin D, IFN- γ, Leishmania-specific antibodies and 
LST reaction were significant explanatory variables. No association between canine leishmaniasis and age or sex 
was found. Table 2 shows the odds ratio (OR) calculated for every significant variable. Thus, for every unit (ng/
mL) increase in plasma 25(OH)D, the risk of having leishmaniasis [(1-OR) * 100] declined by 14.09%. Likewise, 
for every one pg/mL increase in plasma IFNγ and every one mm increase in LST, the risk of having leishmaniasis 
declined by 0.24% and 14.11%, respectively. Finally, for every OD increase in ELISA CTLA, the risk of having 
leishmaniasis increased by 1.64%. In addition, according to the multivariate logistic regression model (Table 2), 
the increase of both 25(OH)D and LST was independently associated with a decreased risk of leishmaniasis by 
21.45% and 28.73% per unit, respectively.
Vitamin D receptor polymorphism. Vitamin D exerts its function by activating the VDR transcrip-
tion factor. We therefore aimed to investigate whether genetic variation within the VDR gene locus is asso-
ciated with the progression of CanL. We sequenced several genomic regions of the canine VDR gene (see 
Materials and Methods) and found four single nucleotide polymorphisms (SNPs), rs851938503 (A > G), 
rs852643282 (C > G), g.6894812 A > G and rs852900542 (T > C). Two of these variants were synonymous 
(rs851938503 and rs852643282) and mapped to exon 4 of the Ensembl’s (www.ensembl.org) annotated 
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transcript ENSCAFT00000014506. The other two SNPs were located in introns 3 (g.6894812 A > G) and 7 
(rs852900542). Genotyping of the 4 VDR SNPs in the cohort of 51 dogs showed intermediate allelic frequencies 
for SNPs g.6894812 A > G and rs851938503, and low minor allele frequencies (MAF) for SNPs rs852643282 and 
rs852900542 (Table 3 and Supplementary Table S2). Importantly, the allelic frequencies of the 4 SNPs were not 
statistically different between the three disease classes and between non-infected vs infected (symptomatic and 













ALT (U/L)1 48.5 [36.0–99.8] 5 (28%) 42.0 [35.2–51.7] 1 (3%) 38.0 [29.5–82.5] 2 (13%) 21–102
ALP (U/L1 43.3 [29.9–53.4] 0 35.2 [24.7–46.7] 0 54.0 [34.0–85.0] 2 (13%) 20–156
Creatinine (mg/dL) 1.0 [0.9–1.2] 0 1.1 [0.9–1.2] 0 1.0 [0.7–1.2] 1 (7%) 0.5–1.5
Urea (mg/dL) 44.4 [33.4–48.0] 0 47.9 [35.9–56.3] 0 47.2 [31.9–2.7] 2 (13%) 21.4–59.9
Albumin (g/dL) 3.3 [3.0–3.8] 1 (6%) 3.1 [2.8–3.3]a 2 (6%) 2.3 [1.5–2.6]a 11 (73%) 2.6–3.3
Beta-globulin (g/dL) 1.4 [1. —1.7] 6 (33%) 1.7 [1.5–2.0]a 2 (6%) 1.8 [1.6–2.1]a 11 (73%) 0.9–1.6
Gamma-globulin (g/dL) 0.6 [0.4–0.7] 1 (6%) 0.7 [0.6–0.8] 3 (9%) 2.5 [1.2–4.1]a 13 (87%) 0.3–0.8
RBC (10^6 cells/uL) 7.1 [6.5–7.6] 1 (6%) 6.8 [6.3–7.3] 0 5.1 [4.6–6.2]a 10 (66%) 5.5–8.5
Platelets (10^3 cells/uL) 296.0 [227.0–353.0] 2 (11%) 286.5 [230.5–337.5] 2 (57%) 407.5 [202.5–581.5] 4 (27%) 200–500
Neutrophiles (10^3 cells/uL) 6.7 [5.19–9.9] 4 (22%) 6.7 [5.4–7.9] 0 6.3 [4.5–7.6] 3 (20%) 3–11.5
Lymphocytes (10^3 cells/uL) 2.6 [1.8–3.4] 1 (46%) 2.6 [1.8–3.3] 1 (3%) 1.8 [1.2–2.3]a 2 (13%) 1–4.8
LAP1 — 2 (11%) — 8 (23%) — 14 (93%) —
Cutaneous — 0 — 5 (14%) — 14 (93%) —
Ocular signs — 0 — 0 — 6 (40%) —
Musculuatrophy — 0 — 1 (3%) — 3 (20%) —
Urinary signs — 0 — 0 — 0 —
GI1 — 0 — 0 — 0 —
Lameness — 0 — 0 — 0 —
Epistaxis — 0 — 0 — 0 —
Anti-Leishmania Antibodies 
(EU) 7.0 [4,29–12,98] 0 15.9 [7.76–38.17]
a 16 (46%) 300.0 [193.85–300.00]a,b 15 (100%) <0.22
Parasite Load in blood 
(parasites/mL blood) 0.0 [0.00–0.00] 0 0.0 [0.00–4.32]
a 12 (34%) 12.4 [5.95–24.69]a,b 11 (73%) 0
Leishmanin skin test 
reaction (mm) 0.0 [0.00–0.00] 0 12.0 [0.00–22.75]
a 23 (66%) 0.0 [0.00–0.00]b 2 (13%) <5
Table 1. Baseline characteristics of the dog population used in the current study. a = Statistically different from 
non-infected dogs (P < 0.05); b = Statistically different from asymptomatic dogs (P < 0.05). 1ALT: Alanin-amino 
tranferase; ALP: Alkaline phosphatase; LAP: Lymphadenopathy; GI: Gastrointestinal signs. 2Number of dogs 
from each group that showed a value out of the reference range for each one of the parameters under evaluation.
Figure 1. Serum vitamin D levels in dogs living in Mallorca and included in the study. Vitamin D status in dogs 
was assessed according to the serum levels of 25-hydroxyvitamin D (25(OH)D) estimated with an ELISA test. 
Non-infected dogs (NI), Leishmania-infected asymptomatic animals (ASYMP), and dogs clinically ill (SYMPT).
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Figure 2. Correlations between vitamin D levels and clinicopathological score (A), Leishmania-specifc 
antibody levels (B) and parasite load in blood samples (C) from Leishmania-infected dogs. Spearman 
correlation indexes (r) and P < 0.05 are shown on the graphs.
Univariate analysis OR (CI 95%)
25(OH)D 0.8591 [0.7810–0.9451]
IFNγ 0.9976 [0.9954–0.9999]
ELISA CTLA 1.0164 [1.0086–1.0243]
LST 0.8589 [0.7687–0.9596]
Multivariate analysis OR (CI 95%)
25(OH)D 0.7855 [0.6499–0.9490]
LST 0.7127 [0.5243–0.9689]
Table 2. Risk factors for canine leishmaniasis. OR: Odds Ratio; CI: Confidence interval.
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Discussion
In this study, we show the existence of a clear association between vitamin D levels and the outcome of VL. 
Indeed, 25(OH)D levels were significantly lower in dogs suffering from clinical leishmaniasis than in asympto-
matic or non-infected animals living in the same area. In addition, vitamin D deficiency in Leishmania-infected 
dogs was strongly correlated with high parasite burden, and the low levels of this vitamin increased the odds of 
suffering from patent leishmaniasis. To the best of our knowledge, this is the first study that describes a statis-
tically significant relationship between vitamin D deficiency and the progression of this parasitic disease. Low 
vitamin D levels in humans have been associated with a large number of diseases including multiple malignances, 
cardiovascular and metabolic disorders, autoimmunity and infectious diseases18, 19, 27. In veterinary medicine, low 
vitamin D levels in dogs have been recently linked with chronic enteropathy28, neoplasia29, and several infectious 
diseases30, 31. The establishment of associations between vitamin D levels and protozoan infections has yielded 
conflicting results in rodent models20, 32–34. However, recent studies have shed light on this issue by demonstrating 
a role for vitamin D in Babesia infections in dogs30, as well as in Plasmodium falciparum infection in children with 
vitamin D insufficiency associated with severe cerebral malaria in Uganda21. The oral administration of Vitamin 
D in rodents before or after Plasmodium berguei ANKA infection protected from cerebral malaria by dampening 
the systemic inflammatory response35. In addition, a recent study in Ethiopian children described vitamin D 
deficiency (<20 ng/mL) in more than half of the paediatric VL patients, although the robust of a relationship 
between vitamin D levels and clinical VL could not be established due to the lack of a healthy control group24. 
In contrast, patients with Post-Kala Azar dermal leishmaniasis— a clinical form characterized by high levels 
of anti-inflammatory IL-10 cytokine — presented a significant increase in vitamin D levels when compared to 
healthy controls36.
Due to the cross-sectional nature of this study, we cannot determine whether the low levels of vitamin D found 
in dogs with VL are the consequence or the cause of this parasitic disease. One hypothesis states that vitamin 
D deficiency in sick dogs could be due to an excess of vitamin consumption during the inflammatory process, 
following a similar pattern as the previously described for vitamin A during chickenpox infection in children37. 
Autier et al. (2014) performed a meta-analysis investigating the consequences of vitamin D supplementation in 
humans. They found that the raise of vitamin D levels did not alter the course of the group of health disorders that 
they studied and proposed that vitamin D deficiency is the result of inflammatory processes related to age, habits, 
and/or diseases38. One of the mechanisms that has been put forward to support this hypothesis is the rapid con-
version of 25(OH)D to the bioactive 1,25(OH)2D by inflammatory cytokines that activate the enzyme catalyzing 
this reaction, CYP27B139. Unfortunately, we could not analyze the 1,25(OH)2D levels in our canine population, as 
its half-life is very short and the test for its evaluation is only available at specialized laboratories.
An alternative hypothesis linking vitamin D and leishmaniasis is that dogs with vitamin D deficiency prior to 
infection might be at a higher risk of developing leishmaniasis. Although vitamin D levels have been determined 
in other canine infectious diseases30, 31, no longitudinal studies have been performed so far. The few longitudinal 
studies conducted in humans reported vitamin D deficiencies prior to clinical manifestations of multiple scle-
rosis40, pulmonary exacerbations in children with cystic fibrosis41, and more severe inflammatory bowel disease 
course42. Within the group of malignant neoplasias, colorectal cancer has been consistently associated with low 
pre-diagnostic vitamin D levels43. Both low UVB light exposure and low vitamin D-dietary intake have been 
suggested as the main causes of this prior vitamin D deficiency in humans. Nonetheless, dogs — unlike man 
— are unable to synthesize vitamin D from cholesterol precursors and UV skin irradiation44. In consequence, 





rs851938503 (A > G) 0.40 0.33 0.32
rs852643282 (C > G) 0.03 0.08 0.05
g.6894812 A > G 0.40 0.35 0.36
rs852900542 (T > C) 0.10 0.10 0.05
Table 3. Minor allele frequencies for each of the 4 vitamin D receptor SNPs genotyped in the study. MAF: 
Minor allele frequency; NI: non-infected dogs, ASYMP: the group of asymptomatic dogs, SYMPT: group of 
dogs suffering clinical leishmaniasis. In the SNP name column cells, the major and the minor alleles of the SNPs 
with an rs identifier are indicated between brackets.
g.6894812 A > G rs851938503 rs852643282 rs852900542
Infected vs 
SYMPT 0.68 0.50 0.53 0.46
NI vs ASYMP 0.62 0.49 0.35 0.61
SYMPT vs 
ASYMP 0.77 0.69 0.45 0.42
NI vs Infected 0.76 0.48 0.45 0.72
Table 4. p-values of the χ2 test of independence comparing the allelic frequencies of the 4 SNPs among the 
phenotypic classes. NI: non-infected dogs, ASYMP: the group of asymptomatic dogs, SYMPT: group of dogs 
suffering clinical leishmaniasis.
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commercial pet food is supplemented, in a routine basis, with this ingredient to ensure that the vitamin D nutri-
tional requirements are met. Two different scenarios could have caused the vitamin D deficiency that we observed 
in our dog population: either the diet of three groups was different or there were other factors involved in vitamin 
D storage/turnover affecting the serum 25(OH)D concentrations prior to disease. A longitudinal study would 
help resolving this relevant issue.
In any case, regardless of which scenario is more plausible, since vitamin D has a direct effect on the innate 
and adaptive immune response, a vitamin D deficiency, would with little doubt, have serious immunological 
consequences during the course of CanL. The activation of Toll-like receptors (TLR), a family of innate immune 
system receptors, triggers an antimicrobial response mediated by vitamin D. Indeed, the expression of VDR and 
CYP27B1 are up-regulated in response to the activation of TLR-2 of human macrophages by Mycobacterium 
tuberculosis antigens11. Activation of TLR-2 in the presence of vitamin D increases the expression of target immu-
nity genes, such as the anti-microbial peptide cathelicidin and β-defensin 445. In the context of Leishmania infec-
tion, lipophosphoglycans and the cytosolic protein silent information regulator 2 from L. infantum activate TLR-2 
in antigen presenting cells. In addition, the peptide BMAP-28 — a cathelicidin member family — has demon-
strated anti-Leishmania effects and immuno-modulatory properties in in vitro cultures46, 47. These results would 
support the hypothesis of a beneficial role of vitamin D in innate immunity against Leishmania infection. In addi-
tion, vitamin D also exerts its immuno-modulatory role by shaping B cell and T cell responses. Exposing human 
B cells to 1,25(OH)2D inhibits their proliferation, IgG secretion andmemory B cell generation, and induces B cell 
apoptosis17. Although further studies to demonstrate the role of vitamin D on canine B cell immunity are needed, 
our results seem to tally with this finding, which may explain the strong inverse correlation between vitamin D 
and anti-Leishmania antibody levels detected in this work (Fig. 2B). On the other hand, there are several studies 
investigating the relationship between vitamin D and T cell immune response during the course of Leishmania 
infection. However, these studies focused on the cutaneous form in a rodent model and, in addition, they yielded 
discrepant results32, 34, 48. Our analysis did not show any association between Leishmania-specific IFN-γ or IL-10 
production and vitamin D levels. As we have highlighted above, vitamin D function could related to the innate 
immune response rather than to adaptive immunity.
Remarkably, both the LST and IFN-γ levels displayed a negative correlation with the progression of leish-
maniasis (clinical signs, serology and blood parasite burden). These results are in keeping with the importance 
that the Th1 immune response has in the control of this disease4. Moreover, our study finds a positive correlation 
between IFN-γ production and the LST reaction suggesting that a LST result could be a marker of IFN-γ status. 
There are few and poorly standardized assays that evaluate T-cell mediated immunity responses in dogs49. Whilst 
the techniques based on the detection of IFN-γ levels may represent an expensive and time-consuming technique, 
the LST test could be a field-adapted tool for the evaluation of Leishmania-specific cell-mediated immunity in 
epidemiological and vaccine-related studies.
Vitamin D activates the VDR transcription factor, which in turn, modulates the expression of several key 
genes involved in the immune response50. For this reason, genetic variation in the VDR gene changing its bind-
ing affinity, activity or protein levels may influence the immunological efficiency of vitamin D. In addition, 
in vitro and knock-out mice experiments have linked VDR to the resistance to Leishmania major infection32. 
Indeed, genetic variants in the VDR gene have also been associated with an increased risk of chronic chagasic 
cardiomyopathy51, malaria severity52, tuberculosis53, and some autoimmune disorders54, 55. Our results showed 
that the four VDR polymorphisms display similar frequencies across the non-infected, asymptomatic, and symp-
tomatic dog groups (Table 3), and no genetic association between these SNPs and disease/infection status were 
observed (Table 4). The 4 SNPs that we investigated span a 10 kb genomic segment encompassing from intron 
3 to intron 7 of the VDR transcript ENSCAFT00000014506. These SNPs are predicted to be either synonymous 
or intronic and should not alter protein function. They were screened as markers to identify any potential func-
tional and causal polymorphism affecting VDR function. Moreover, two of our variants were present at low 
allelic frequencies in our population and this could have resulted in a low statistical power to detect a genetic 
association given the small sample size of our study. However, the canine VDR gene has 10 exons and spans a 
58 kb long region, so we cannot rule out the hypothesis that other genetic variants elsewhere in the VDR gene 
affects the function or activity of VDR and, ultimately, impacts on the susceptibility to CanL infection. Moreover, 
a more comprehensive study involving additional genes from the vitamin D pathway such as CYP2R1, which 
converts vitamin D into 25(OH)D, would provide a deeper understanding of the relationship between genetic 
susceptibility to CanL and vitamin D metabolism. Larger studies involving more individuals and a higher den-
sity of genetic variants would increase the power to detect genetic associations in the vitamin D pathway to CanL 
susceptibility.
In summary, we report that progression of VL is strongly associated with vitamin D deficiency in dogs. Our 
findings suggest that vitamin D pathway may be involved in the immune response against Leishmania and that 
this may affect the susceptibility to suffer from the disease. A future goal would be to investigate if vitamin D 
supplementation may mitigate the symptoms and progression of this disease in infected dogs. Vitamin D sup-
plementation could be a cost-effective and feasible strategy to be used both as an adjuvant therapy and to protect 
against the disease.
Material and Methods
Dogs and samples. All procedures were approved by the Universitat Autonoma de Barcelona’s Ethical 
Committee of Human and Animal Experimentation (Spain) in compliance with national (Royal Decree 
1201/2005) and European Union regulations (European Directive 86/609/CE) for projects using animals for 
research purposes. Sixty-eight dogs attended at the Mon Veterinari Clinical Hospital of Manacor (Mallorca, 
Spain) were included in the study after their owners’ consent. The sample included 31 females and 38 males 
from different breeds, and ages ranged from 6 months to 15 years (4 ± 2.7 years). Prior to sampling, all dogs were 
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examined for clinical signs compatible with CanL, such as weight loss, lymphadenopathy, cutaneous lesions, 
and ocular, gastrointestinal, and renal alterations. Blood samples were collected by jugular venipuncture. Serum 
was obtained after centrifugation at 3,000 rpm for 20 min, and stored at −20 °C until further use. Blood-EDTA 
samples used for Leishmania DNA detection were frozen at −20 °C before DNA extraction, and blood-heparin 
samples were analyzed before 24 h.
Clinical signs, biochemistry, and hematological values were scored as previously described with some mod-
ifications56. Briefly, clinical signs compatible with leishmaniasis such as cutaneous lesions, ocular signs, and 
epistaxis were scored 0–3 as indicated in Table S1. Both biochemistry and hematological results scored 1 point for 
each abnormal value (Table S1). These scores were summed up to obtain an overall clinico-pathological score for 
each dog. A score greater than 5 was considered as indicative of patent clinical leishmaniasis.
Crude total L. infantum antigen (CTLA)-based ELISA. B cell function was analyzed by measuring 
anti-Leishmania antibody levels with an ELISA technique, as previously described57. Briefly, microtiter plates 
were coated with 2 µg of CTLA per well and sequentially incubated with sera and protein A conjugated to horse-
radish peroxidase (Pierce). Working dilutions were 1/400 and 1/15,000 for sera dilution and protein A-HRP 
dilutions, respectively. Absorbance values were read at 492 nm in an automatic microELISA reader (Anthos 2001, 
Anthos Labtec Instruments). Results were expressed in ELISA units (EU), referred to a known positive serum 
used as a calibrator, and arbitrarily set to 1 EU. Cut-off value (mean + 3 SD) for 76 dogs from a non-endemic area 
was set at 0.220 OD.
Real-Time PCR amplification of Leishmania DNA in blood samples. Parasite load was deter-
mined by quantitative real-time PCR (qPCR) in blood samples. DNA was extracted using the High Pure PCR 
Template Kit (Roche). Leishmania infantum DNA was specifically detected and quantified with a TaqMan 
qPCR assay (Applied Biosystems). We employed a previously reported protocol58 with some modifications. The 
qPCR assay was designed to target a conserved DNA regions of the kinetoplast L. infantum genome. Primer 
sequences were LEISH-1 5′-AAC TTT TCT GGT CCT CCG GGT AG-3′, LEISH-2 5′-ACC CCC AGT TTC 
CCG CC-3′, and the TaqMan-MGB probe FAM-5′-AAA AAT GGG TGC AGA AAT-3′- MGB. The thermal 
cycling profile was 50 °C for 2 min, 95 °C for 10 min, 40 cycles at 95 °C for 15 seconds, and 60 °C for 1 min. 
Analyses were performed in a Step One Plus Real Time PCR System device (Applied Biosystems Laboratories). 
Each sample plus a negative control was analyzed in triplicate. The number of parasites per mL of blood was 
calculated using a standard curve generated with L. infantum DNA extracted from 1 × 107 parasites by using 
serial dilutions from 103 to 10−3 parasites. This technique was sensitive enough to detect 0.001 parasites per 
reaction with a dynamic range of 107. The median slope of three different standard curves was −3.44, and 
the qPCR efficiency was 98%. Quantification was linear between 103 and 10−2 parasites per reaction tube 
(correlation = 0.99).
Leishmanin skin test (LST). In vivo T cell-mediated immunity was determined in each dog by measuring 
delayed type hypersensitivity (DTH) response against the leishmanin reagent. The leishmanin reagent consisted 
of a suspension of 3 × 108 inactivated L. infantum (MHOM/FR/78/LEM75) promastigotes per mL in a 0.4% 
phenol-saline solution. A volume of 0.1 mL of leishmanin solution was intradermally inoculated to dogs. The 
delayed-type hypersensitivity response was assessed by measuring the size of the indurated and erythematous 
area (mean of two perpendicular diameters) observed at 72 h post injection. A response against leishmanin rea-
gent >5 mm was considered as an LST positive result59.
Whole blood assay and cytokine detection. The in vitro Leishmania-specific immune response was 
evaluated by measuring pro-inflammatory (IFN-γ) and regulatory (IL-10) cytokine levels expressed by antigen 
stimulated lymphocytes in whole blood assays60. Blood collected in tubes containing heparin anticoagulant was 
diluted 1:10 in RPMI-1640 medium supplemented with 10% v/v heat-inactivated foetal calf serum, 10 mM Hepes 
buffer, 100 IU/mL penicillin, and 100 mg/mL streptomycin (Gibco, Paisley, UK). Cells were incubated in 96-well 
flat bottom plastic culture plates at 1.8 × 106 cells per well with soluble L. infantum antigen (10 µg/mL), concana-
valin A (2.5 µg/ mL), or media (unstimulated), for a period of 5 days at 37 °C in 5% CO2. Supernatants from each 
of the three replicate wells were pooled and stored at −80 °C.
Quantikine ELISA kits (R&D systems) were used to detect IFN-γ and IL-10 in supernatant cultures following 
manufacturer’s recommendations. Background levels in the non-stimulated control wells were extracted from the 
values on the antigen-stimulated wells to quantify the antigen-specific cytokine production.
Determination of Vitamin D levels. Circulating levels of 25(OH)D are considered to be the most reliable 
estimate of overall vitamin D status because this is a stable circulating metabolite of vitamin D and its concentra-
tion is nearly 1,000-fold higher than that of 1,25(OH)2D327. Thus, 25(OH)D levels were assessed in serum sam-
ples using a competitive direct enzyme-linked immuno-sorbent assay (IDS 25-Hydroxy Vitamin D Direct EIA 
kit, Immunodiagnostic Systems Ltd.) according to the manufacturer instructions and employing an automatic 
micro-ELISA reader (Anthos 2001, Anthos Labtec Instruments). The concentration of 25(OH)D in each sample 
was calculated using a four-parameter logistic curve fit (Graph Pad Prism v3.02), and results were expressed in 
ng/mL units. The threshold for 25(OH)D deficiency was set at <20 ng/mL (<50 nmol/L) as reported by Ross 
et al.61.
Genetic variation at the Vitamin D receptor. With the aim to identify DNA variants in the VDR gene 
segregating in our dog population, primers targeting VDR exons 5, 8 and 9 and introns 4, 5, 7 and 8 were designed 
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(Supplementary Figure S1). These regions were PCR amplified and sequenced in ten dogs. PCR reactions were 
prepared in a final volume of 15 µL containing 1.5 µL 10× PCR buffer, 0.25 mM of each dideoxynucleotide, 
2.5 mM MgCl2, 0.3 µM of each primer, 0.75 U Amplitaq Gold DNA polymerase (ThermoFisher Scientific), and 
6–22 ng of genomic DNA. Thermal cycling conditions included an initial step at 95 °C for 10 min, and 35 cycles of 
denaturation at 95 °C for 1 min, primer annealing at 62 °C (PCR amplicon 2) or 66 °C (PCR amplicon 1) for 1 min, 
and extension at 72 °C for 1 min. Subsequently, a final extension step at 72 °C for 7 min was carried out. Amplicons 
were purified with the ExoSAP-IT PCR cleanup kit (Affymetrix) and sequenced in both directions using the PCR 
primers and the Big Dye Terminator Cycle Sequencing Kit v1.1 (Applied Biosystems). Sequencing reactions were 
run in an ABI 3730 DNA Analyzer (Applied Biosystems) platform. Sequences were aligned with the SeqScape® 
v2.1.1..0 software (Applied Biosystems). Four polymorphic positions were identified and genotyped by direct 
sequencing of PCR products in a cohort of 51 samples including 15 non-infected, 25 asymptomatic, and 11 
symptomatic dogs.
Data analysis. In the unadjusted analysis, the comparisons between dog groups were performed using the 
Mann-Whitney U Test and the correlations between different parameters by Spearman’s rank correlation coeffi-
cient. We then adjusted for potential confounders between clinical leishmaniasis risk and vitamin D deficiency, 
considering clinical leishmaniasis as the dependent variable (outcome) and vitamin D levels, sex, age, serology, 
LST and cytokine levels as independent variables (predictors) using both univariate and multivariate regression 
analyses. To determine the genetic association of each polymorphism with the infection and disease status, the 
allelic frequencies of the three phenotypic groups were compared using the χ2 test for independence. All statisti-
cal tests were performed using SPSS version 15.0 (SPSS software, SPSS Inc). A P-value ≤ 0.05 was considered to 
be significant.
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